A pivotal new medical review reveals that osteoporosis (OP) should be reclassified as a disease profoundly driven by chronic inflammation and oxidative stress, moving the primary focus beyond hormonal and age-related factors alone. This paradigm shift is rapidly opening the door for new therapeutic strategies that target the body’s immune and cellular metabolic pathways.
The Mechanism of Bone Destruction
The core finding is that a persistent “pro-inflammatory state” and the accumulation of Reactive Oxygen Species (ROS) aggressively dismantle the body’s skeletal balance.
1. Oxidative Stress: The Rust on the Bones
Oxidative stress, caused by an imbalance between free radicals (ROS) and the body’s natural antioxidants, is shown to exert a dual-harmful effect on bone health:
-
-
Accelerated Bone Resorption: Elevated ROS levels overstimulate the bone-resorbing cells, osteoclasts, enhancing their differentiation and activity. This process is mediated through key signaling cascades like NF- $\kappa$ B, MAPKs (ERK, p38-MAPK, and JNK), and the downstream activation of NFATc1.
-
Impaired Bone Formation: ROS causes osteoblasts (bone-forming cells) and osteocytes to undergo apoptosis (cell death). It also suppresses osteoblast differentiation by inhibiting vital pathways like Wnt/ $\beta$-catenin and Hedgehog signaling. Prolonged exposure to hydrogen peroxide ($H_{2}O_{2}$) also suppresses osteoblast proliferation via the mTORC1/AMPK pathway.
-
2. Chronic Inflammation: The Cytokine Assault
Pro-inflammatory cytokines, especially those released following estrogen deficiency or in systemic inflammatory diseases, create a toxic environment for bone cells.
-
Key Cytokine Players: TNF- $\alpha$, IL-1, IL-6, and IL-17 are identified as major drivers. They collectively upregulate RANKL, the primary signal for osteoclast activation, thereby enhancing bone resorption.
-
The IL-17 Pathway: Produced mainly by T helper 17 (Th17) cells, IL-17 is strongly implicated in postmenopausal OP and is found to increase osteoclast precursors’ susceptibility to RANKL activation.
-
NLRP3 Inflammasome: Studies in mice show that knocking out the NLRP3 inflammasome drastically suppresses pro-inflammatory factors like IL-1 $\beta$ and TNF- $\alpha$ after estrogen withdrawal, highlighting this complex as a central node of inflammation-mediated bone loss.
New Avenues for Treatment
The research outlines that traditional anti-osteoporotic drugs, like bisphosphonates, do not address the root inflammatory and oxidative issues. This has spurred interest in novel, targeted interventions:
Precision Anti-Inflammatory Biologics
Drugs designed to neutralize specific inflammatory cytokines show promise in bone preservation, often in patients with conditions like rheumatoid arthritis (RA):
-
IL-6 Inhibitors (Tocilizumab/Sarilumab): These not only suppress inflammation but also improve the overall balance of bone biomarkers, stimulating the formation marker P1NP while reducing resorption markers like CTX-1.
-
JAK/STAT Inhibitors: Small-molecule inhibitors like Baricitinib and Peficitinib block multiple inflammatory pathways (IL-6, IL-23), restoring joint structure and stopping bone loss in animal models.
Antioxidant and Nutritional Strategies
Targeting oxidative stress offers a preventative or complementary approach:
-
Polyphenols: Compounds like Resveratrol and Icariin promote osteoblast development by activating the Wnt/ $\beta$-catenin pathway.
-
Vitamins: Vitamin D (VD2/VD3) preserves bone homeostasis by regulating the Vitamin D Receptor (VDR) in both osteoblasts and osteoclasts, leading to decreased RANKL expression. Vitamin C and Vitamin K2 are also highlighted for promoting osteoblast maturation and enhancing mineralization.
-
Synthetic Antioxidants: Drugs like Ebselen and N-acetylcysteine (NAC) reduce oxidative damage and suppress osteoclast differentiation by acting as enzyme mimics or boosting glutathione levels.
| Antioxidant Agent | Origin/Type | Mechanism on Bone Remodeling | Clinical/Preclinical Evidence |
| Resveratrol | Natural (Polyphenol) | Stabilizes $\beta$-catenin to activate the Wnt/ $\beta$-catenin pathway, promoting osteoblast development. | Inconsistent clinical results due to low bioavailability, but one controlled trial showed it slowed bone loss in the lumbar spine and femoral neck in postmenopausal women. |
| Lycopene | Natural (Carotenoid) | Inhibits osteoclast differentiation and enhances osteoblast proliferation via WNT/ $\beta$-catenin and ERK1/2 pathways. | Clinical studies in postmenopausal women show it significantly decreases the bone resorption marker N-telopeptide (NTx) and improves BMD in small cohorts. |
| Ebselen | Synthetic (Organoselenium) | Mimics the antioxidant enzyme glutathione peroxidase (GPx), inhibiting osteoclastogenesis and activating the PI3K/Akt pathway in BMSCs. | Highly effective in preclinical models (e.g., inhibiting inflammatory bone destruction in mice). Limited human clinical data available. |
| Vitamin K2 | Natural (Menaquinone) | Promotes osteoblast precursor proliferation and enhances mineralization. Causes osteocalcin to undergo $\gamma$-carboxylation, which strengthens bones. | Appears beneficial and safe for postmenopausal women by lowering uncarboxylated osteocalcin (uc-OC) and increasing lumbar spine BMD, but fracture risk data are limited. |
Future Challenges for Researchers
The authors conclude that several critical questions remain before these treatments can be widely adopted:
-
Therapeutic Paradoxes: Some cytokines, like IL-17 and IL-6, exhibit dual (sometimes opposing) roles in bone metabolism. Future drugs must be designed to selectively target the destructive inflammatory signaling while preserving the beneficial effects.
-
Clinical Translation: Poor bioavailability plagues natural compounds, and synthetic antioxidants lack comprehensive long-term safety data in humans.
-
Emerging Mechanisms: Deeper research is needed into fields like microRNAs (e.g., miR-214-3p, which suppresses osteoblasts) and mitochondrial dysfunction, which are crucial for cellular senescence and OP.
The ultimate goal, the researchers state, is to integrate genetics, proteomics, and metabolomics to establish a precision diagnosis and treatment system for osteoporosis, shifting from passive treatment to active, targeted prevention.
Source Luo J, Li L, Shi W, Xu K, Shen Y and Dai B (2025) Oxidative stress and inflammation: roles in osteoporosis. Frontiers in Immunology 16:1611932. doi: 10.3389/fimmu.2025.1611932.
